Holly E Rawizza1,2, Kristin M Darin3, Regina Oladokun4, Biobele Brown4, Babatunde Ogunbosi4, Nkiruka David5, Sulaimon Akanmu6, Oluremi Olaitan7, Charlotte Chang2, Kimberly K Scarsi8, Prosper Okonkwo7, Phyllis J Kanki2. 1. Brigham and Women's Hospital, Boston, MA, USA. 2. Harvard T.H. Chan School of Public Health, Boston, MA, USA. 3. Northwestern University School of Professional Studies, Chicago, IL, USA. 4. College of Medicine, University of Ibadan, University College Hospital, Ibadan, Nigeria. 5. Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria. 6. University of Lagos, Lagos State, Nigeria. 7. APIN Public Health Initiatives, Abuja, Nigeria. 8. University of Nebraska Medical Center, Omaha, NE, USA.
Abstract
BACKGROUND: TB is the leading cause of death among HIV-infected children, yet treatment options for those who require PI-based ART are suboptimal. Rifabutin is the preferred rifamycin for adults on PI-based ART; only one study has evaluated its use among children on PIs and two of six children developed treatment-limiting neutropenia. METHODS: Since 2009, rifabutin has been available for HIV/TB-coinfected children requiring PI-based ART in the Harvard/APIN programme in Nigeria. We retrospectively analysed laboratory and clinical toxicities at baseline and during rifabutin therapy, and examined HIV/TB outcomes. RESULTS: Between 2009 and 2015, 48 children received rifabutin-containing TB therapy with PI (lopinavir/ritonavir)-based ART: 50% were female with a median (IQR) baseline age of 1.7 (0.9-5.0) years and a median (IQR) CD4+ cell percentage of 15% (9%-25%); 52% were ART experienced. Eighty-five percent completed the 6 month rifabutin course with resolution of TB symptoms and 79% were retained in care at 12 months. Adverse events (grade 1-4) were more common at baseline (27%) than during rifabutin treatment (15%) (P = 0.006). Absolute neutrophil count was lower during rifabutin compared with baseline (median = 1762 versus 2976 cells/mm3, respectively), but only one instance (2%) of grade 3 neutropenia occurred during rifabutin treatment. CONCLUSIONS: With clinical and laboratory monitoring, our data suggest that rifabutin is a safe option for TB therapy among children on PI-based ART. By contrast with the only other study of this combination in children, severe neutropenia was rare. Furthermore, outcomes from this cohort suggest that rifabutin is effective, and a novel option for children who require PI-based ART. Additional study of rifabutin plus PIs in children is urgently needed.
BACKGROUND:TB is the leading cause of death among HIV-infectedchildren, yet treatment options for those who require PI-based ART are suboptimal. Rifabutin is the preferred rifamycin for adults on PI-based ART; only one study has evaluated its use among children on PIs and two of six children developed treatment-limiting neutropenia. METHODS: Since 2009, rifabutin has been available for HIV/TB-coinfected children requiring PI-based ART in the Harvard/APIN programme in Nigeria. We retrospectively analysed laboratory and clinical toxicities at baseline and during rifabutin therapy, and examined HIV/TB outcomes. RESULTS: Between 2009 and 2015, 48 children received rifabutin-containing TB therapy with PI (lopinavir/ritonavir)-based ART: 50% were female with a median (IQR) baseline age of 1.7 (0.9-5.0) years and a median (IQR) CD4+ cell percentage of 15% (9%-25%); 52% were ART experienced. Eighty-five percent completed the 6 month rifabutin course with resolution of TB symptoms and 79% were retained in care at 12 months. Adverse events (grade 1-4) were more common at baseline (27%) than during rifabutin treatment (15%) (P = 0.006). Absolute neutrophil count was lower during rifabutin compared with baseline (median = 1762 versus 2976 cells/mm3, respectively), but only one instance (2%) of grade 3 neutropenia occurred during rifabutin treatment. CONCLUSIONS: With clinical and laboratory monitoring, our data suggest that rifabutin is a safe option for TB therapy among children on PI-based ART. By contrast with the only other study of this combination in children, severe neutropenia was rare. Furthermore, outcomes from this cohort suggest that rifabutin is effective, and a novel option for children who require PI-based ART. Additional study of rifabutin plus PIs in children is urgently needed.
Authors: W C Buck; D Olson; M M Kabue; S Ahmed; L K Nchama; A Munthali; M C Hosseinipour; P N Kazembe Journal: Int J Tuberc Lung Dis Date: 2013-11 Impact factor: 2.373
Authors: Hanneke M J Nijland; Rafaëlla F A L'homme; Gerard A Rongen; Peter van Uden; Reinout van Crevel; Martin J Boeree; Rob E Aarnoutse; Peter P Koopmans; David M Burger Journal: AIDS Date: 2008-05-11 Impact factor: 4.177
Authors: Remko van Leeuwen; Christine Katlama; Robert L Murphy; Kathleen Squires; José Gatell; Andrej Horban; Bonaventura Clotet; Shlomo Staszewski; Arne van Eeden; Nathan Clumeck; Mauro Moroni; Andrew T Pavia; Reinhold E Schmidt; Juan Gonzalez-Lahoz; Julio Montaner; Francisco Antunes; Robert Gulick; Dénes Bánhegyi; Marc van der Valk; Peter Reiss; Liesbeth van Weert; Frank van Leth; Victoria A Johnson; Jean-Pierre Sommadossi; Joep M Lange Journal: AIDS Date: 2003-05-02 Impact factor: 4.177
Authors: Avy Violari; Jane C Lindsey; Michael D Hughes; Hilda A Mujuru; Linda Barlow-Mosha; Portia Kamthunzi; Benjamin H Chi; Mark F Cotton; Harry Moultrie; Sandhya Khadse; Werner Schimana; Raziya Bobat; Lynette Purdue; Susan H Eshleman; Elaine J Abrams; Linda Millar; Elizabeth Petzold; Lynne M Mofenson; Patrick Jean-Philippe; Paul Palumbo Journal: N Engl J Med Date: 2012-06-21 Impact factor: 91.245
Authors: Alberto Matteelli; Paola Villani; Anna Cristina C Carvalho; Issa El-Hamad; Maria Cusato; Alessandra Apostoli; Claudio Marcantoni; Alessandra Calabresi; Sarah Dal Zoppo; Sara Bigoni; Mario Regazzi Journal: J Antimicrob Chemother Date: 2012-06-07 Impact factor: 5.790
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Gregory L Kearns; Susan M Abdel-Rahman; Sarah W Alander; Douglas L Blowey; J Steven Leeder; Ralph E Kauffman Journal: N Engl J Med Date: 2003-09-18 Impact factor: 91.245
Authors: Yuan Ren; James J C Nuttall; Claire Egbers; Brian S Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen M McIlleron Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Keneth Iceland Kasozi; Gniewko Niedbała; Mohammed Alqarni; Gerald Zirintunda; Fred Ssempijja; Simon Peter Musinguzi; Ibe Michael Usman; Kevin Matama; Helal F Hetta; Ngala Elvis Mbiydzenyuy; Gaber El-Saber Batiha; Amany Magdy Beshbishy; Susan Christina Welburn Journal: Front Public Health Date: 2020-12-10
Authors: Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790